ASP-7991
- Generic Name
- ASP-7991
A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis
Phase 2
Completed
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 62
- Registration Number
- NCT02133404
Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 36
- Registration Number
- NCT01872013
Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis
Phase 1
Completed
- Conditions
- Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis TherapyPharmacodynamics of ASP7991Pharmacokinetics of ASP7991
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 14
- Registration Number
- NCT01872026
A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy Volunteers
- First Posted Date
- 2012-08-30
- Last Posted Date
- 2012-08-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 56
- Registration Number
- NCT01675518
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath